Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$5.17
Price+18.04%
$0.79
$891.367m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$8.356m
-
1y CAGR-
3y CAGR-
5y CAGR-$311.549m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.95
-
1y CAGR-
3y CAGR-
5y CAGR$665.658m
$728.841m
Assets$63.183m
Liabilities$34.183m
Debt4.7%
-0.1x
Debt to EBITDA-$262.059m
-
1y CAGR-
3y CAGR-
5y CAGR